About Us

At Rapid Nexus, we’ve developed a cutting-edge technology that accelerates wound healing by reducing infections and promoting rapid tissue recovery. Our breakthrough solution is unparalleled in the industry, it is specifically engineered to address both acute and chronic diabetic wounds.

Led by Dr. Kalmeta, our dedicated team is committed to expanding access to this life-changing technology. We are working to bring Hemastyl™ to the market, with the goal of improving healing outcomes and enhancing the quality of life for those who need it most.

About Us

At Rapid Nexus, we’ve developed a cutting-edge technology that accelerates wound healing by reducing infections and promoting rapid tissue recovery. Our breakthrough solution is unparalleled in the industry, it is specifically engineered to address both acute and chronic diabetic wounds.

Led by Dr. Kalmeta, our dedicated team is committed to expanding access to this life-changing technology. We are working to bring Hemastyl™ to the market, with the goal of improving healing outcomes and enhancing the quality of life for those who need it most.

Meet the Team

Dr. Margaret Kalmeta

FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Margaret Kalmeta is a doctor of dental surgery with decades of oral surgery clinical practice.  Building and successfully exiting several startup practices, she went on to develop and patent novel tissue and bone growth technologies which were 500% faster in jawbone healing. Learning that amputations measured over 1,000 per day in the US alone, Dr. Kalmeta transferred her technology to the neuropathy and diabetic foot market to address this critical unmet patient need.

Christine Pasciak

CHIEF OPERATIONS OFFICER

Christine Pasciak has formed strategic relationships, alliances, and successfully exited several successful businesses since 1998. Christine has, in total, over 30 years of experience in the health science field, from having a clinical background to being a management executive. As COO for Rapid Nexus, Christine has formed strategic relationships and alliances and built our manufacturing capabilities to scale our technology.​

Brian E. Cain

BOARD MEMBER

Brian E. Cain has over twenty years of commercialization planning and execution for companies such as Shering-Plough (acquired by Merck), Organon (acquired by Schering), Bayer products (acquired by Shering), Pharmacia (acquired by Pfizer), Celgene (acquired by BMS) where he proactively created Commercial and Market Research Digital teams that leveraged analytics and market intelligence to penetrate new markets. Other noteworthy commercialization goals were achieved for Ortho-McNeil and Bristol-Myers Squibb.​

Deepak Sahu, MBA, MPH

BOARD MEMBER

Deepak Sahu is the former managing partner at Alira Health and current managing director at Trinity Life Sciences. Deepak works closely with strategic investors, private equities, and medical devices companies at various stages of maturity and leads acquisition efforts. He sold Kerecis for $1.3B to Coloplast in 2023 and also has acquired and led numerous growth strategies and investment projects. Deepak has an MBA in International Management and MPH in Health Management from Harvard T.H. Chan School of Public Health.

Meet the Team

Dr. Margaret Kalmeta

FOUNDER & CHIEF EXECUTIVE OFFICER

Dr. Margaret Kalmeta is a doctor of dental surgery with decades of oral surgery clinical practice.  Building and successfully exiting several startup practices, she went on to develop and patent novel tissue and bone growth technologies which were 500% faster in jawbone healing. Learning that amputations measured over 1,000 per day in the US alone, Dr. Kalmeta transferred her technology to the neuropathy and diabetic foot market to address this critical unmet patient need.

Christine Pasciak

CHIEF OPERATIONS OFFICER

Christine Pasciak has formed strategic relationships, alliances, and successfully exited several successful businesses since 1998. Christine has, in total, over 30 years of experience in the health science field, from having a clinical background to being a management executive. As COO for Rapid Nexus, Christine has formed strategic relationships and alliances and built our manufacturing capabilities to scale our technology.​

Brian E. Cain

BOARD MEMBER

Brian E. Cain has over twenty years of commercialization planning and execution for companies such as Shering-Plough (acquired by Merck), Organon (acquired by Schering), Bayer products (acquired by Shering), Pharmacia (acquired by Pfizer), Celgene (acquired by BMS) where he proactively created Commercial and Market Research Digital teams that leveraged analytics and market intelligence to penetrate new markets. Other noteworthy commercialization goals were achieved for Ortho-McNeil and Bristol-Myers Squibb.​

Deepak Sahu, MBA, MPH

BOARD MEMBER

Deepak Sahu is the former managing partner at Alira Health and current managing director at Trinity Life Sciences. Deepak works closely with strategic investors, private equities, and medical devices companies at various stages of maturity and leads acquisition efforts. He sold Kerecis for $1.3B to Coloplast in 2023 and also has acquired and led numerous growth strategies and investment projects. Deepak has an MBA in International Management and MPH in Health Management from Harvard T.H. Chan School of Public Health.

Dr. Margaret Kalmeta
Founder & Chief Executive Officer

Dr. Margaret Kalmeta is a doctor of dental surgery with decades of oral surgery clinical practice.  Building and successfully exiting several startup practices, she went on to develop and patent novel tissue and bone growth technologies which were 500% faster in jawbone healing. Learning that amputations measured over 1,000 per day in the US alone, Dr. Kalmeta transferred her technology to the neuropathy and diabetic foot market to address this critical unmet patient need.

Christine Pasciak
Chief Operations Officer

Christine Pasciak has formed strategic relationships, alliances, and successfully exited several successful businesses since 1998. Christine has, in total, over 30 years of experience in the health science field, from having a clinical background to being a management executive. As COO for Rapid Nexus, Christine has formed strategic relationships and alliances and built our manufacturing capabilities to scale our technology.

Brian E. Cain
Board Member

Brian E. Cain has over twenty years of commercialization planning and execution for companies such as Shering-Plough (acquired by Merck), Organon (acquired by Schering), Bayer products (acquired by Shering), Pharmacia (acquired by Pfizer), Celgene (acquired by BMS) where he proactively created Commercial and Market Research Digital teams that leveraged analytics and market intelligence to penetrate new markets. Other noteworthy commercialization goals were achieved for Ortho-McNeil and Bristol-Myers Squibb.

Deepak Sahu, MBA, MPH
Board Member

Deepak Sahu is the former managing partner at Alira Health and current managing director at Trinity Life Sciences. Deepak works closely with strategic investors, private equities, and medical devices companies at various stages of maturity and leads acquisition efforts. He sold Kerecis for $1.3B to Coloplast in 2023 and also has acquired and led numerous growth strategies and investment projects. Deepak has an MBA in International Management and MPH in Health Management from Harvard T.H. Chan School of Public Health.

Our Mission

“Our mission is to give doctors the advanced tools they need in order to treat infection, close non-healing wounds and prevent amputations, which are especially prevalent in the disproportionately affected populations.”

Unlike competing products that just protect the tissue, Dr. Kalmeta developed a top-down approach that rebuilds the surrounding tissue and then works its way back into the bed of the wound.

This method stems from her background as an oral surgeon, where she invented a post-surgical rapid healing technology to help heal patients’ periodontal tissue damage and gum infections.

While working to get this product out to market, she met a diabetic man who lost all of his limbs due to amputation.

“I met a diabetic patient in the nursing home who just had all of his limbs amputated from nonhealing wounds. I couldn’t believe what I was seeing, they seemed like simple wounds but ended up destroying his ability to live” – Dr. Kalmeta.

This pushed Dr. Kalmeta to lead a self-funded international effort to adapt her mouth infection technology to the advanced wound market, where it has already prevented numerous amputations.

Why Our Work Matters​

Every 22 seconds, a limb is amputated somewhere around the globe due to a non-healing wound that gets infected. In the US, 427 people undergo amputations daily, and 186,000 annually, due to diabetes. These diabetic non-healing wounds are primarily caused by one underlying condition: neuropathy.

Diabetic neuropathy is particularly concerning as it elevates the risk of foot-related complications such as calluses, infections, and damage to bones and joints. These problems, along with sensory loss and poor circulation, can result in diabetic foot ulcers (DFUs). DFUs are slow-healing or chronic wounds that can become infected and may eventually require an amputation if not properly treated.

 

Rapid Nexus NWS’ Hemastyl™ is the most effective solution to treat neuropathy and heal chronic non-healing wounds that have otherwise been non‐responsive to other forms of medical procedures. Radiographic and visual evidence shows this patented technology closed combination hard and soft tissue wounds 500% faster than competitor products, even for patients with chronic wounds and diabetes. This breakthrough treatment has been refined into Hemastyl™, the first-ever wound healing product designed specifically for peri-wound care and neuropathy.

This technology is set to disrupt the $13 billion global peripheral neuropathy and diabetic foot ulcer markets that are expected to nearly double by 2032 due to rising rates of diabetes.